Matinas BioPharma Holdings, Inc. Logo

Matinas BioPharma Holdings, Inc.

Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.

MTNB | US

Overview

Corporate Details

ISIN(s):
US5768101058
LEI:
Country:
United States of America
Address:
1545 ROUTE 206 SOUTH, 7921 BEDMINSTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel products to address unmet medical needs. The company's core technology is its proprietary Lipid Nano-Crystal (LNC) platform, which enables the safe, oral, and intracellular delivery of small molecules, nucleic acids, and other therapeutics. Its lead product candidate, MAT2203, is an oral formulation of the anti-fungal drug amphotericin B. In addition to infectious diseases, Matinas is pursuing discovery programs using its LNC platform for applications in oncology and inflammation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Matinas BioPharma Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matinas BioPharma Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matinas BioPharma Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan 2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea 078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea 236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea 086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan 2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America MRK

Talk to a Data Expert

Have a question? We'll get back to you promptly.